Mapping neurotransmitter networks with PET: An example on serotonin and opioid systems

Human Brain Mapping

Volumn 35, Issue 5, 2014, Pages 1875-1884

  Tuominen, Lauri ^a,b   Nummenmaa, Lauri ^a,c   Keltikangas Järvinen, Liisa ^d   Raitakari, Olli ^e   Hietala, Jarmo ^a,b  

^a TURKU PET CENTRE   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

^c AALTO UNIVERSITY   (Finland)

^d UNIVERSITY OF HELSINKI   (Finland)

^e UNIVERSITY OF TURKU   (Finland)

Author keywords

Connectivity; Correlation; Positron emission tomography; Serotonin transporter; opioid receptor

Indexed keywords

CARFENTANIL C 11; MADAM C 11; MU OPIATE RECEPTOR; SEROTONIN RECEPTOR; SEROTONIN TRANSPORTER; TRACER; UNCLASSIFIED DRUG; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; BENZYLAMINE DERIVATIVE; CARFENTANIL; FENTANYL; N,N-DIMETHYL-2-(2-AMINO-4-METHYLPHENYLTHIO)BENZYLAMINE; SEROTONIN;

ADULT; AMYGDALOID NUCLEUS; ARTICLE; BRAIN MAPPING; CAUDATE NUCLEUS; CORPUS STRIATUM; FEMALE; HUMAN; HUMAN EXPERIMENT; IMAGE PROCESSING; IN VIVO STUDY; MALE; MESENCEPHALON; NERVE CELL NETWORK; NORMAL HUMAN; PARIETAL CORTEX; POSITRON EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PUTAMEN; SEROTONINERGIC SYSTEM; THALAMUS; VOXEL BASED MORPHOMETRY; ANALOGS AND DERIVATIVES; ANATOMY AND HISTOLOGY; BRAIN; METABOLISM; MIDDLE AGED; SCINTISCANNING;

ADULT; BENZYLAMINES; BRAIN; BRAIN MAPPING; FEMALE; FENTANYL; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; MIDDLE AGED; NEUROTRANSMITTER AGENTS; POSITRON-EMISSION TOMOGRAPHY; RECEPTORS, OPIOID, MU; SEROTONIN;

EID: 84898043660     PISSN: 10659471     EISSN: 10970193     Source Type: Journal    
DOI: 10.1002/hbm.22298     Document Type: Article

References (53)

1. Bailer UF, Frank GK, Price JC, Meltzer CC, Becker C, Mathis CA, Wagner A, Barbarich-Marsteller NC, Bloss CS, Putnam K, Schork NJ, Gamst A, Kaye WH (2013): Interaction between serotonin transporter and dopamine D2/D3 receptor radioligand measures is associated with harm avoidant symptoms in anorexia and bulimia nervosa. Psychiatry Res. 211: 160-168. doi: 10.1016/j.pscychresns.2012.06.010.
2. Bencherif B, Fuchs PN, Sheth R, Dannals RF, Campbell JN, Frost JJ (2002): Pain activation of human supraspinal opioid pathways as demonstrated by [11C]-carfentanil and positron emission tomography (PET). Pain 99: 589-598.
3. Berger B, Rothmaier AK, Wedekind F, Zentner J, Feuerstein TJ, Jackisch R (2006): Presynaptic opioid receptors on noradrenergic and serotonergic neurons in the human as compared to the rat neocortex. Br J Pharmacol 148: 795-806.
4. Bose SK, Mehta MA, Selvaraj S, Howes OD, Hinz R, Rabiner EA, Grasby PM, Turkheimer FE, Murthy V (2011): Presynaptic 5-HT1A is related to 5-HTT receptor density in the human brain. Neuropsychopharmacology 36: 2258-2265.
5. Cervenka S, Varrone A, Fransen E, Halldin C, Farde L (2010): PET studies of D2-receptor binding in striatal and extrastriatal brain regions: Biochemical support in vivo for separate dopaminergic systems in humans. Synapse 64: 478-485.
6. Comtat C, Bataille F, Michel C, Jones JP, Sibomana M, Janeiro L, Trebossen R (2004): OSEM-3D reconstruction strategies for the ECAT HRRT. Conf Rec 2004 IEEE Nucl Sci Symp Med Imaging Conf 6: 3492-3496.
7. Conturo TE, Lori NF, Cull TS, Akbudak E, Snyder AZ, Shimony JS, Mckinstry RC, Burton H, Raichle ME (1999): Tracking neuronal fiber pathways in the living human brain. Proc Natl Acad Sci USA 96: 10422-10427.
8. Emond P, Vercouillie J, Innis R, Chalon S, Mavel S, Frangin Y, Halldin C, Besnard JC, Guilloteau D (2002): Substituted diphenyl sulfides as selective serotonin transporter ligands: synthesis and in vitro evaluation. J Med Chem 45: 1253-1258.
9. Endres CJ, Bencherif B, Hilton J, Madar I, Frost JJ (2003): Quantification of brain mu-opioid receptors with [11C]carfentanil: reference-tissue methods. Nucl Med Biol 30: 177-186.
10. Erritzoe D, Holst K, Frokjaer VG, Licht CL, Kalbitzer J, Nielsen FA, Svarer C, Madsen J, Knudsen G (2010): A nonlinear relationship between cerebral serotonin transporter and 5-HT(2A) receptor binding: An in vivo molecular imaging study in humans. J Neurosci 30: 3391-3397.
11. Frost JJ, Wagner HN Jr, Dannals RF, Ravert HT, Links JM, Wilson AA, Burns HD, Wong DF, Mcpherson RW, Rosenbaum AE (1985): Imaging opiate receptors in the human brain by positron tomography. J Comput Assist Tomogr 9: 231-236.
12. Gunn RN, Lammertsma AA, Hume SP, Cunningham VJ (1997): Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. Neuroimage 6: 279-287.
13. Hahn A, Lanzenberger R, Wadsak W, Spindelegger C, Moser U, Mien LK, Mitterhauser M, Kasper S (2010): Escitalopram enhances the association of serotonin-1A autoreceptors to heteroreceptors in anxiety disorders. J Neurosci 30: 14482-14489.
14. Hietala J, Någren K, Lehikoinen P, Ruotsalainen U, Syvälahti E (1999): Measurement of striatal D2 dopamine receptor density and affinity with [11C]-raclopride in vivo: A test-retest analysis. J Cereb Blood Flow Metab 19(2): 210-217.
15. Hirvonen J, Hietala J (2011): Dysfunctional brain networks and genetic risk for schizophrenia: Specific neurotransmitter systems. CNS Neurosci Ther 17: 89-96.
16. Hirvonen J, Aalto S, Hagelberg N, Maksimow A, Ingman K, Oikonen V, Virkkala J, Nagren K, Scheinin H (2009): Measurement of central mu-opioid receptor binding in vivo with PET and [11C]carfentanil: A test-retest study in healthy subjects. Eur J Nucl Med Mol Imaging 36: 275-286.
17. Hirvonen M, Laakso A, Nagren K, Rinne JO, Pohjalainen T, Hietala J (2004): C957T polymorphism of the dopamine D2 receptor (DRD2) gene affects striatal DRD2 availability in vivo. Mol Psychiatry 9: 1060-1061.
18. Hirvonen MM, Lumme V, Hirvonen J, Pesonen U, Nagren K, Vahlberg T, Scheinin H, Hietala J (2009): C957T polymorphism of the human dopamine D2 receptor gene predicts extrastriatal dopamine receptor availability in vivo. Prog Neuropsychopharmacol Biol Psychiatry 33: 630-636.
19. Ide S, Fujiwara S, Fujiwara M, Sora I, Ikeda K, Minami M, Uhl GR, Ishihara K (2010): Antidepressant-like effect of venlafaxine is abolished in mu-opioid receptor-knockout mice. J Pharmacol Sci 114: 107-110.
20. Jovanovic H, Lundberg J, Karlsson P, Cerin A, Saijo T, Varrone A, Halldin C, Nordstrom AL (2008): Sex differences in the serotonin 1A receptor and serotonin transporter binding in the human brain measured by PET. Neuroimage 39: 1408-1419.
21. Kobiella A, Reimold M, Ulshöfer DE, Ikonomidou VN, Vollmert C, Vollstädt-Klein S, Rietschel M, Reischl G, Heinz A, Smolka MN (2011): How the serotonin transporter 5-HTTLPR polymorphism influences amygdala function: The roles of in vivo serotonin transporter expression and amygdala structure. Transl Psychiatry 1: e37.
22. Laje G, Cannon DM, Allen AS, Klaver JM, Peck SA, Liu X, Manji HK, Drevets WC, Mcmahon FJ (2010): Genetic variation in HTR2A influences serotonin transporter binding potential as measured using PET and [11C]DASB. Int J Neuropsychopharmacol 13: 715-724.
23. Lammertsma AA, Hume SP (1996): Simplified reference tissue model for PET receptor studies. Neuroimage 4: 153-158.
24. Liberzon I, Zubieta JK, Fig LM, Phan KL, Koeppe RA, Taylor SF (2002): mu-Opioid receptors and limbic responses to aversive emotional stimuli. Proc Natl Acad Sci USA 99: 7084-7089.
25. Lopez-Gimenez JF, Vilaro MT, Milligan G (2008): Morphine desensitization, internalization, and down-regulation of the mu opioid receptor is facilitated by serotonin 5-hydroxytryptamine2A receptor coactivation. Mol Pharmacol 74: 1278-1291.
26. Lundberg J, Odano I, Olsson H, Halldin C, Farde L (2005): Quantification of 11C-MADAM binding to the serotonin transporter in the human brain. J Nucl Med 46: 1505-1515.
27. Lundberg J, Halldin C, Farde L (2006): Measurement of serotonin transporter binding with PET and [11C]MADAM: A test-retest reproducibility study. Synapse 60: 256-263.
28. Lundberg J, Borg J, Halldin C, Farde L (2007): A PET study on regional coexpression of 5-HT1A receptors and 5-HTT in the human brain. Psychopharmacology (Berl) 195: 425-433.
29. Maguire P, Tsai N, Kamal J, Cometta-Morini C, Upton C, Loew G (1992): Pharmacological profiles of fentanyl analogs at mu, delta and kappa opiate receptors. Eur J Pharmacol 213: 219-225.
30. Maldjian JA, Laurienti PJ, Kraft RA, Burdette JH (2003): An automated method for neuroanatomic and cytoarchitectonic atlas-based interrogation of fMRI data sets. Neuroimage 19: 1233-1239.
31. Marsman A, van den Heuvel MP, Klomp DW, Kahn RS, Luijten PR, Hulshoff Pol HE (2013): Glutamate in schizophrenia: A focused review and meta-analysis of 1H-MRS studiesSchizophr Bull 39: 120-129. doi: 10.1093/schbul/sbr069.
32. Martikainen IK, Hirvonen J, Kajander J, Hagelberg N, Mansikka H, Nagren K, Hietala J, Pertovaara A (2007): Correlation of human cold pressor pain responses with 5-HT(1A) receptor binding in the brain. Brain Res 1172: 21-31.
33. Mayberg HS (1997): Limbic-cortical dysregulation: A proposed model of depression. J Neuropsychiatry Clin Neurosci 9: 471-481.
34. Meyer JH (2007): Imaging the serotonin transporter during major depressive disorder and antidepressant treatment. J Psychiatry Neurosci 32: 86-102.
35. Moore RY, Halaris AE, Jones BE (1978): Serotonin neurons of the midbrain raphe: ascending projections. J Comp Neurol 180: 417-438.
36. Murthy NV, Selvaraj S, Cowen PJ, Bhagwagar Z, Riedel WJ, Peers P, Kennedy JL, Sahakian BJ, Laruelle MA, Rabiner EA, Grasby PM (2010): Serotonin transporter polymorphisms (SLC6A4 insertion/deletion and rs25531) do not affect the availability of 5-HTT to [11C] DASB binding in the living human brain. Neuroimage 52: 50-54.
37. Nakamura K, Sekine Y, Ouchi Y, Tsujii M, Yoshikawa E, Futatsubashi M, Tsuchiya KJ, Sugihara G, Iwata Y, Suzuki K, Matsuzaki H, Suda S, Sugiyama T, Takei N, Mori N (2010): Brain serotonin and dopamine transporter bindings in adults with high-functioning autism. Arch Gen Psychiatry 67: 59-68.
38. Palomero-Gallagher N, Vogt BA, Schleicher A, Mayberg HS, Zilles K (2009): Receptor architecture of human cingulate cortex: Evaluation of the four-region neurobiological model. Hum Brain Mapp 30: 2336-2355.
39. Price JL, Drevets WC (2010): Neurocircuitry of mood disorders. Neuropsychopharmacology 35: 192-216.
40. Rahmim A, Cheng JC, Blinder S, Camborde ML, Sossi V (2005): Statistical dynamic image reconstruction in state-of-the-art high-resolution PET. Phys Med Biol 50: 4887-4912.
41. Raichle ME, Macleod AM, Snyder AZ, Powers WJ, Gusnard DA, Shulman GL (2001): A default mode of brain function. Proc Natl Acad Sci USA 98: 676-682.
42. Ray R, Ruparel K, Newberg A, Wileyto EP, Loughead JW, Divgi C, Blendy JA, Logan J, Zubieta JK, Lerman C (2011): Human Mu Opioid Receptor (OPRM1 A118G) polymorphism is associated with brain mu-opioid receptor binding potential in smokers. Proc Natl Acad Sci USA 108: 9268-9273.
43. Sbrenna S, Marti M, Morari M, Calo G, Guerrini R, Beani L, Bianchi C (2000): Modulation of 5-hydroxytryptamine efflux from rat cortical synaptosomes by opioids and nociception. Br J Pharmacol 130: 425-433.
44. Scott D, Stohler, C, Koeppe R, Zubieta J (2007): Time-course of change in [11C]carfentanil and [11C]raclopride binding potential after a nonpharmacological challenge. Synapse 61: 707-714.
45. Simmons ML, Chavkin C (1996): Endogenous opioid regulation of hippocampal function. Int Rev Neurobiol 39: 145-196.
46. Sporns O, Tononi G, Kotter R (2005): The human connectome: A structural description of the human brain. PLoS Comput Biol 1: e42.
47. Takano H, Ito H, Takahashi H, Arakawa R, Okumura M, Kodaka F, Otsuka T, Kato M, Suhara T (2011): Serotonergic neurotransmission in the living human brain: A positron emission tomography study using [(11)C]dasb and [(11)C]WAY100635 in young healthy men. Synapse 65: 624-633.
48. Tao R, Auerbach SB (1995): Involvement of the dorsal raphe but not median raphe nucleus in morphine-induced increases in serotonin release in the rat forebrain. Neuroscience 68: 553-561.
49. Tao R, Auerbach SB (2002): Opioid receptor subtypes differentially modulate serotonin efflux in the rat central nervous system. J Pharmacol Exp Ther 303: 549-556.
50. Tarkiainen J, Vercouille J, Emond P, Sandell J, Hiltunen J, Frangin Y, Guilloteau D, Halldin C (2001): Carbon-11 labelling of MADAM in two different positions: A highly selective PET radioligand for the serotonin transporter. J Labelled Compd Radiopharm 44: 1013-1023.
51. Varnas K, Halldin C, Hall H (2004): Autoradiographic distribution of serotonin transporters and receptor subtypes in human brain. Hum Brain Mapp 22: 246-260.
52. Willeit M, Praschak-Rieder N (2010): Imaging the effects of genetic polymorphisms on radioligand binding in the living human brain: A review on genetic neuroreceptor imaging of monoaminergic systems in psychiatry. Neuroimage 53: 878-892.
53. Zilles K, Amunts K (2009): Receptor mapping: Architecture of the human cerebral cortex. Curr Opin Neurol 22: 331-339.